Management of CKD Stage 3a

Laboratory Assessment

The American Diabetes Association recommends measuring urinary albumin-to-creatinine ratio (UACR) to quantify proteinuria and stratify risk, as albuminuria ≥300 mg/g significantly increases cardiovascular and progression risk 1, 2, 4
Serum creatinine should be measured to confirm eGFR calculation and establish baseline 1
A complete metabolic panel, including electrolytes, should be performed to screen for metabolic acidosis, hyperkalemia, and mineral bone disease 2
A complete blood count should be evaluated to assess for anemia, which becomes prevalent when eGFR falls below 60 mL/min/1.73 m² 2
Hemoglobin A1c should be measured if diabetes is present or suspected 1
Parathyroid hormone (PTH) and 25-hydroxyvitamin D levels should be screened to assess for metabolic bone disease 2

The American Heart Association recommends targeting blood pressure <130/80 mmHg for all patients with CKD stage 3a 5, 3
ACE inhibitor or ARB should be used as first-line therapy, particularly if UACR ≥30 mg/g 1, 2, 5, 3
ACE inhibitor or ARB is reasonable even without significant albuminuria to slow kidney disease progression 3
Combination ACE inhibitor plus ARB therapy should be avoided due to increased risk of adverse events without additional benefit 3

Statin or statin/ezetimibe combination therapy should be initiated for patients ≥50 years (Grade 1A recommendation) 3
Statin therapy should be initiated for patients 18-49 years with known coronary disease, diabetes mellitus, prior ischemic stroke, or estimated 10-year cardiovascular risk >10% 3
SGLT2 inhibitors should be considered for patients with type 2 diabetes and CKD stage 3a, as they reduce risks of CKD progression, cardiovascular events, and hypoglycemia 2
Low-dose aspirin should be used for secondary prevention in patients with established cardiovascular disease 3

A plant-based "Mediterranean-style" diet should be recommended to reduce cardiovascular risk 3, 6
Sodium restriction should be advised to help control blood pressure 3
Protein intake should be approximately 0.8 g/kg/day, and high protein diets should be avoided 1
Limiting alcohol, meats, and high-fructose corn syrup is recommended 3
Smoking cessation is mandatory 6
Moderate-intensity physical activity for at least 150 minutes per week should be encouraged 6
Weight management to achieve optimal body mass index is recommended 6

All medications should be reviewed for appropriate dosing based on eGFR 45-59 mL/min/1.73 m² 3
Nephrotoxic medications, particularly NSAIDs, should be avoided as they can accelerate kidney function decline 3
Metformin should not be initiated if eGFR <45 mL/min/1.73 m², and benefits/risks should be reassessed if eGFR falls below 45 2
Metformin should be temporarily discontinued before iodinated contrast imaging procedures 2
Target hemoglobin A1c ≤7% for patients with diabetes to delay CKD progression 1
GLP-1 receptor agonists should be considered as they reduce cardiovascular events and may slow CKD progression 2

Patients should be evaluated at each visit or every 6-12 months for elevated blood pressure, volume overload, electrolyte abnormalities, metabolic acidosis, anemia, and metabolic bone disease 2, 3

Patients with rapid decline in eGFR, significant albuminuria, refractory hypertension, persistent electrolyte abnormalities, hereditary kidney disease, or uncertain etiology of CKD should be referred to nephrology 3, 1, 4